Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a ...
Summit's ivonescimab data has sparked interest in BioNTech's BNT327, and its potential to follow a similar path and gain value. Goldman incorporates risk-adjusted revenue forecasts that currently ...
The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...
BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per ...
In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...
BioNTech's Q3 revenue rose to €1.244 billion ($1.36 billion), driven by earlier COVID-19 vaccine approvals. Q3 net profit climbed to €198.1 million, with EPS increasing to 81 cents from 66 ...
Vergleichsweise frühe Zulassungen für angepasste Coronaimpfstoffe haben die Umsätze des Mainzer Unternehmens Biontech im dritten Quartal nach oben getrieben. Insgesamt beliefen sich die Erlöse ...
Auf einen Blick zu BioNTech: - Umsatz in den ersten 9 Monaten 2024 bei 1,56 Milliarden Euro - Nettoverlust von 924,8 Millionen Euro, bedingt durch hohe F&E-Kosten - Umsatzprognose für 2024 am ...
(RTTNews) - Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a net profit of 198.1 million euros or 0.81 euros per share for the third quarter ...
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327 ...
Conference call and webcast scheduled for November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET) MAINZ, Germany, November 4, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback